流式细胞术评估骨髓增生异常综合征/肿瘤。

Flow Cytometric Assessment of Myelodysplastic Syndromes/Neoplasms.

机构信息

Translational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, 825 Eastlake Avenue East, Seattle, WA 98109, USA.

SI-HMDS, Haematology, UHBW NHS Foundation Trust, Bristol Royal Infirmary, Upper Maudlin Street, Bristol, BS2 8HW, UK.

出版信息

Clin Lab Med. 2023 Dec;43(4):521-547. doi: 10.1016/j.cll.2023.06.006. Epub 2023 Aug 7.

DOI:10.1016/j.cll.2023.06.006

PMID:37865501

Abstract

Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous class of hematopoietic stem cell neoplasms characterized by ineffective hematopoiesis leading to peripheral cytopenias. This group of diseases is typically diagnosed using a combination of clinical, morphologic, and genetic criteria. Many studies have described the value of multiparametric flow cytometry (MFC) in the diagnosis, classification, and prognostication of MDS. This review summarizes the approach to MDS diagnosis and immunophenotypic characterization using MFC and describes the current state while highlighting future opportunities and potential pitfalls.

摘要

骨髓增生异常综合征/肿瘤（MDS）是一组异质性造血干细胞肿瘤，其特征为无效造血导致外周血细胞减少。该疾病组通常采用临床、形态学和遗传学标准相结合的方法进行诊断。许多研究已经描述了多参数流式细胞术（MFC）在 MDS 诊断、分类和预后评估中的价值。本综述总结了使用 MFC 进行 MDS 诊断和免疫表型特征分析的方法，并描述了当前的现状，同时强调了未来的机会和潜在的陷阱。